Advertisement

Anaplastic Thyroid Carcinoma

  • Christian Passler
  • Reza Asari
  • Christian Scheuba
  • Bruno Niederle
Chapter
  • 1.1k Downloads

12.13 Conclusion

Multimodal treatment using hyperfractionated radiotherapy, chemotherapy, and surgery may be the treatment of choice for ATC. Surgery plays an important role because local tumor control cannot be achieved without debulking of large tumor masses.

Current evidence indicates that undifferentiated thyroid carcinoma originates from follicular cells. Therefore prognostic factors are related primarily to the extent of the disease at presentation. A small number of patients with completely resectable tumors (mainly as incidental ATC in the form of small foci of ATC in differentiated carcinomas) may be cured by aggressive surgery in combination with radiotherapy and chemotherapy. Nevertheless, in most patients death from ATC cannot be avoided, since multimodal treatment does not have much influence on distant metastases and thus on the survival rate. However, quality of life can be improved. It is probably less severe to die from distant metastases, than from suffocation due to failure of local tumor control. Although future therapeutic aspects are promising, clinical trials showing their impact on survival are still lacking.

Keywords

Thyroid Cancer Thyroid Carcinoma Medullary Thyroid Carcinoma Local Tumor Control Anaplastic Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ain KB (1999) Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64–69PubMedCrossRefGoogle Scholar
  2. 2.
    Demeter JG, De Jong SA, Lawrence AM, Paloyan E (1991) Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 110:956–961; discussion 961–963PubMedGoogle Scholar
  3. 3.
    Hadar T, Mor C, Shvero J, Levy R, Segal K (1993) Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 19:511–516PubMedGoogle Scholar
  4. 4.
    Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP (1995) Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 17:41–47; discussion 47–48PubMedGoogle Scholar
  5. 5.
    Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79:564–573PubMedCrossRefGoogle Scholar
  6. 6.
    Bakiri F, Djemli FK, Mokrane LA, Djidel FK (1998) The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer 82:1146–1153PubMedCrossRefGoogle Scholar
  7. 7.
    Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A (2001) Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27:260–264PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez JM, Pinero A, Ortiz S, Moreno A, Sola J, Soria T, Robles R, Parrilla P (2000) Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg 166:34–38PubMedGoogle Scholar
  9. 9.
    Thomas GG Jr, Buckwalter JA (1973) Poorly differentiated neoplasms of the thyroid gland. Ann Surg 177:632–642PubMedGoogle Scholar
  10. 10.
    Demeure MJ, Clark OH (1990) Surgery in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 19:663–683PubMedGoogle Scholar
  11. 11.
    Schmid KW, Gerber M, Tötsch M, Sandbichler P, Ladurner D (1990) Zur Inzidenz anaplastischer Schilddrüsenkarzinome und dem prognostischen Aussagewert differenzierter Anteile beim anaplastischen Karzinom. Wien Klin Wochenschr 102:4Google Scholar
  12. 12.
    Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 384:284–293PubMedCrossRefGoogle Scholar
  13. 13.
    Bacher-Stier C, Riccabona G, Totsch M, Kemmler G, Oberaigner W, Moncayo R (1997) Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid 7:733–741PubMedGoogle Scholar
  14. 14.
    Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726PubMedGoogle Scholar
  15. 15.
    Pettersson B, Coleman MP, Ron E, Adami HO (1996) Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer 65:13–19PubMedCrossRefGoogle Scholar
  16. 16.
    Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ, MacFarlane GJ (1993) The epidemiology of thyroid carcinoma. Crit Rev Oncog 4:25–52PubMedGoogle Scholar
  17. 17.
    Hellman P, Goretzki P, Witte J, Röher HD (2001) Follicular thyroid carcinoma. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  18. 18.
    Holting T, Moller P, Tschahargane C, Meybier H, Buhr H, Herfarth C (1990) Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg 14:291–294; discussion 295PubMedCrossRefGoogle Scholar
  19. 19.
    Levendag PC, De Porre PM, van Putten WL (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128PubMedGoogle Scholar
  20. 20.
    Nel CJ, van Heerden JA, Goellner JR, Gharib H, McConahey WM, Taylor WF, Grant CS (1985) Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 60:51–58PubMedGoogle Scholar
  21. 21.
    Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA (1990) Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66:321–330PubMedCrossRefGoogle Scholar
  22. 22.
    Junor EJ, Paul J, Reed NS (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18:83–88PubMedGoogle Scholar
  23. 23.
    McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028–1034PubMedCrossRefGoogle Scholar
  24. 24.
    Lu WT, Lin JD, Huang HS, Chao TC (1998) Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol Head Neck Surg 118:728–731PubMedCrossRefGoogle Scholar
  25. 25.
    Carcangiu ML, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135–158PubMedGoogle Scholar
  26. 26.
    Agrawal S, Rao RS, Parikh EM, Parikh HK, Borges AM, Sampat MB (1996) Histologic trends in thyroid cancer 1969–1993: a clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid. J Surg Oncol 63:251–255PubMedCrossRefGoogle Scholar
  27. 27.
    Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR, Stoler DL (2003) Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662–670PubMedCrossRefGoogle Scholar
  28. 28.
    Nishiyama RH, Dunn EL, Thompson NW (1972) Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 30:113–127PubMedCrossRefGoogle Scholar
  29. 29.
    Hollinsky C, Kober F, Hermann M, Loicht U, Keminger K (1990) [Prognostic factors in highly malignant thyroid tumors]. Wien Klin Wochenschr 102:249–253PubMedGoogle Scholar
  30. 30.
    Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622PubMedCrossRefGoogle Scholar
  31. 31.
    Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, Iwasaki H (2002) The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131:245–248PubMedCrossRefGoogle Scholar
  32. 32.
    Moreno A, Rodriguez JM, Sola J, Soria T, Parrilla P (1993) Prognostic value of the tall call variety of papillary cancer of the thyroid. Eur J Surg Oncol 19:517–521Google Scholar
  33. 33.
    Saunders CA, Nayar R (1999) Anaplastic spindle-cell squamous carcinoma arising in association with tall-cell papillary cancer of the thyroid: a potential pitfall. Diagn Cytopathol 21:413–418PubMedCrossRefGoogle Scholar
  34. 34.
    Lam KY, Lo CY, Chan KW, Wan KY (2000) Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 231:329–338PubMedCrossRefGoogle Scholar
  35. 35.
    Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369–1371PubMedGoogle Scholar
  36. 36.
    Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753–1760PubMedGoogle Scholar
  37. 37.
    Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179–184PubMedCrossRefGoogle Scholar
  38. 38.
    Farid NR (2001) P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 24:536–545PubMedGoogle Scholar
  39. 39.
    Carty S (2001) Anaplastic thyroid carcinoma, thyroid metastases and lymphoma. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  40. 40.
    Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64PubMedCrossRefGoogle Scholar
  41. 41.
    Pasieka JL (2003) Anaplastic thyroid cancer. Curr Opin Oncol 15:78–83PubMedCrossRefGoogle Scholar
  42. 42.
    Voutilainen PE, Multanen M, Haapiainen RK, Leppaniemi AK, Sivula AH (1999) Anaplastic thyroid carcinoma survival. World J Surg 23:975–978; discussion 978–979PubMedCrossRefGoogle Scholar
  43. 43.
    Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L (1996) Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 40:953–958PubMedGoogle Scholar
  44. 44.
    Besic N (2003) The role of initial debulking surgery in the management of anaplastic thyroid carcinoma. Surgery 133:453–454; author reply 454–455PubMedCrossRefGoogle Scholar
  45. 45.
    Ordonez N, Balogh Z, Matias-Gulu X, Evans H, Farid NR, Fagin JA, Kitamura Y, Taillini G, Eng C, Haigh PI, Faquin WC, Sugitani I, Gluffrida D, Boerner S (2004) Undifferentiated (anaplastic) carcinoma. In: Delellis RA, Lloyd RV, Heitz PU (eds) Pathology and genetics of tumours of the endocrine organs. Eng Charis, Lyon, pp 77–80Google Scholar
  46. 46.
    DeLellis RA, Williams ED (2004) Thyroid and parathyroid tumours: introduction. In: Delellis RA, Lloyd RV, Heitz PU (eds) Pathology and genetics of tumours of the endocrine organs. Eng Charis, Lyon, pp 51–56Google Scholar
  47. 47.
    Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, Monden M (1996) Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18:36–41PubMedCrossRefGoogle Scholar
  48. 48.
    Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 22:725–730PubMedCrossRefGoogle Scholar
  49. 49.
    Staunton MD (1994) Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 20:613–621PubMedGoogle Scholar
  50. 50.
    Pacheco-Ojeda LA, Martinez AL, Alvarez M (2001) Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg 86:117–121PubMedGoogle Scholar
  51. 51.
    Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342PubMedCrossRefGoogle Scholar
  52. 52.
    Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr (1978) Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 41:2267–2275PubMedCrossRefGoogle Scholar
  53. 53.
    Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160PubMedCrossRefGoogle Scholar
  54. 54.
    Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564–566PubMedCrossRefGoogle Scholar
  55. 55.
    Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853PubMedCrossRefGoogle Scholar
  56. 56.
    Goldman JM, Goren EN, Cohen MH, Webber BL, Brennan MF, Robbins J (1980) Anaplastic thyroid carcinoma: long-term survival after radical surgery. J Surg Oncol 14:389–394PubMedCrossRefGoogle Scholar
  57. 57.
    Machens A, Hinze R, Lautenschlager C, Thomusch O, Dunst J, Dralle H (2001) Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid 11:373–380PubMedCrossRefGoogle Scholar
  58. 58.
    Zimmermann G, Hermann M, Kober F, Ladurner D, Pimpl W (1990) Intra-und postoperative Komplikationen in der Chirurgie hochmaligner Schilddrüsentumore. Wien Klin Wochenschr 102:10–11Google Scholar
  59. 59.
    Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372–2375PubMedCrossRefGoogle Scholar
  60. 60.
    Tallroth E, Wallin G, Lundell G, Lowhagen T, Einhorn J (1987) Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 60:1428–1431PubMedCrossRefGoogle Scholar
  61. 61.
    Hölting T, Meybier H, Buhr H (1990) Stellenwert der Tracheotomie in der Behandlung des respiratorischen Notfalls beim anaplastischen Schilddrüsenkarzinom. Wien Klin Wochenschr 102:264–266PubMedGoogle Scholar
  62. 62.
    Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y, Matsuzawa Y, Monden M (1997) Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757–2762PubMedGoogle Scholar
  63. 63.
    Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303–310PubMedGoogle Scholar
  64. 64.
    Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:405–407PubMedGoogle Scholar
  65. 65.
    De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV (1991) Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475–480PubMedGoogle Scholar
  66. 66.
    Kober F, Heiss A, Keminger K, Depisch D (1990) [Chemotherapy of highly malignant thyroid tumors]. Wien Klin Wochenschr 102:274–276PubMedGoogle Scholar
  67. 67.
    Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650–3653PubMedCrossRefGoogle Scholar
  68. 68.
    Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRefGoogle Scholar
  69. 69.
    Veness MJ, Porter GS, Morgan GJ (2004) Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. Aust N Z J Surg 74:559–562CrossRefGoogle Scholar
  70. 70.
    Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R (1996) Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56:765–771PubMedGoogle Scholar
  71. 71.
    Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A (1997) p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14:729–740PubMedCrossRefGoogle Scholar
  72. 72.
    Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S, Niwa M (2000) Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res 20:2723–2728PubMedGoogle Scholar
  73. 73.
    Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081–4086PubMedCrossRefGoogle Scholar
  74. 74.
    Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG (2001) Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11:315–325PubMedCrossRefGoogle Scholar
  75. 75.
    Hama Y, Shimizu T, Hosaka S, Sugenoya A, Usuda N (1997) Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 49:239–247PubMedGoogle Scholar
  76. 76.
    Franzen A, Heldin NE (2001) BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285:773–781PubMedCrossRefGoogle Scholar
  77. 77.
    Kotchetkov R, Cinatl J, Krivtchik AA, Vogel JU, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J Jr (2001) Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 21:1035–1042PubMedGoogle Scholar
  78. 78.
    Wang CY, Zhomg WB, Chang TC, Lai SM, Tsai YF (2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021–3026PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Christian Passler
    • 1
  • Reza Asari
    • 1
  • Christian Scheuba
    • 1
  • Bruno Niederle
    • 2
  1. 1.Division of Endocrine Surgery, Department of SurgeryVienny University HospitalViennaAustria
  2. 2.Division of Endocrine Surgery, Department of SurgeryMedical University of ViennaViennaAustria

Personalised recommendations